Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Insider sale under 10b5-1 plan: A company director, Charles W. Newhall III, reported sales of a total of 25,000 shares of Supernus Pharmaceuticals, Inc. (SUPN) executed on
The reporter certified the transactions were made pursuant to a Rule 10b5-1 plan and provided weighted-price ranges:
Supernus Pharmaceuticals (SUPN) notice reports a proposed sale of 59,900 common shares, with an aggregate market value of $2,875,200, to be sold on or about
Notice of proposed sale under Rule 144 for Supernus Pharmaceuticals, Inc. (SUPN) reports an intended sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of
Supernus Pharmaceuticals (SUPN) reported insider equity activity by its President, CEO and Director on 10/02/2025. The reporting person acquired 20,000 and 19,320 shares of common stock at $0 upon settlement of performance share units granted in 2021 and 2024. To cover taxes, the company withheld 7,796 and 7,529 shares at $46.21.
Following these transactions, the reporting person directly beneficially owned 1,185,228 shares. An additional 1,005,600 shares were beneficially owned indirectly via the KBT Trust. The performance share unit awards vested based on achievement of individual performance objectives set in 2021 and 2024.
Supernus Pharmaceuticals insider activity shows the company's President and CEO, Jack A. Khattar, completed option exercise and open-market sale transactions on 10/02/2025. He exercised 2,267 employee stock options at an exercise price of $25.3 per share, resulting in direct ownership of those 2,267 shares. On the same date he sold 1,904 shares in multiple trades at a weighted average price of $48.06. After these transactions the reporting person directly beneficially owned 1,161,233 shares and indirectly held 1,005,600 shares through the KBT Trust.
The exercise was made under an employee option schedule that vests in installments beginning 02/24/2018, and the sale was executed pursuant to a 10b5-1 trading plan adopted 11/14/2024. The filer offers to provide detailed breakdowns of sale prices within the reported $48.00–$48.08 range on request.
Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,904 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $91,468.16 and an approximate sale date of 10/02/2025 on NASDAQ. The filing states the shares were acquired the same day by exercise of stock options and paid in cash.
The notice also lists multiple prior 10b5-1 sales by the same account during Aug–Oct 2025, including transactions such as 40,173 shares for $1,931,063.89 on 10/01/2025 and several large sales in August and September 2025. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Jack A. Khattar, President and CEO and a director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on 10/01/2025 showing the acquisition and sale of company common stock. He acquired 53,785 shares pursuant to an employee stock option with an exercise price of $25.30 and also sold 40,173 shares at a weighted average price of $48.07. The acquisition was made under a 10b5-1 trading plan adopted November 14, 2024, and the sale occurred in multiple transactions at prices ranging from $48.00 to $48.25.
After these transactions Mr. Khattar directly beneficially owns 1,160,870 shares and indirectly (through the KBT Trust) holds 1,005,600 shares, for a combined reported interest disclosed on the form. The exercised option vests in four equal installments beginning on 02/24/2018 and expires on 02/24/2027.
Insider notice to sell 40,173 common shares of Supernus Pharmaceuticals (SUPN) is reported under Form 144. The sale is scheduled for 10/01/2025 through Morgan Stanley Smith Barney and the aggregate market value of the proposed sale is $1,919,867.67. The shares were acquired on 10/01/2025 by exercise of stock options and payment was made in cash on the same date. The filing shows 56,073,088 shares outstanding for the class referenced. The filing also lists multiple prior 10b5-1 sales by the same account over the past three months totaling 304,123 shares.
Jack A. Khattar, President, CEO and director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/30/2025. He exercised an employee stock option to acquire 11,510 shares at an exercise price of $25.30 per share under a plan adopted 02/24/2018, and sold 8,588 shares in multiple trades at a weighted average price of $48.25 (individual sale prices ranged $48.00–$48.44). After these transactions Mr. Khattar beneficially owned 1,147,258 shares directly and an additional 1,005,600 shares indirectly through the KBT Trust. The option activity leaves 137,302 option shares outstanding held directly.
Form 144 filing for SUPN reports a proposed sale of 8,588 shares of common stock to be executed through Morgan Stanley Smith Barney LLC on 09/30/2025 on NASDAQ with an aggregate market value of $408,788.80. The filing states these shares were acquired and will be paid for on 09/30/2025 by exercise of stock options from the issuer. The document also lists multiple recent Rule 10b5-1 sales by Jack A. Khattar totaling numerous transactions in August and September 2025, including sales on 09/29/2025, 09/23/2025, 09/22/2025, and earlier dates, each showing amounts and gross proceeds. The filing shows total shares outstanding of 56,073,088, providing context for the size of the proposed sale within the company's capitalization.